Keep pulling the thread on Abbas Kazimi.
Nimbus Therapeutics sold its TYK2 inhibitor, zazocytinib, to Takeda Pharmaceuticals in late 2022 for $4 billion upfront and $2 billion in potential milestones.
Phase 3 results for zazocytinib suggest the drug will become a multi-billion dollar blockbuster.
Abbas Kazimi has led corporate and business development transactions at Nimbus Therapeutics totaling over $8 billion.
Nimbus Therapeutics was structured by the law firm Goodwin with an LLC holding company and separate C-corp subsidiaries for each asset, a "hub and spoke" model designed to facilitate single-asset acquisitions.
The acquisition of Nimbus Therapeutics' ACC inhibitor program by Gilead Sciences was a $1.2 billion deal.
Nimbus Therapeutics received $400 million upfront from Gilead Sciences for its ACC program, followed by a $200 million milestone payment within six months, for a total of $600 million within one year.
Nimbus Therapeutics' TYK2 inhibitor achieved 1.5 million-fold selectivity over other JAK family members.
Nimbus Therapeutics filed and won a lawsuit against Bristol-Myers Squibb to regain control of its TYK2 inhibitor program after Bristol-Myers Squibb acquired its partner, Celgene.
Phase 3 data for Takeda's TYK2 inhibitor shows approximately one-third of psoriasis patients achieved a PASI 100 score, compared to 10-15% for Bristol-Myers Squibb's competing drug.
Takeda could file for regulatory approval for its TYK2 inhibitor this year.
Takeda plans to spend an additional $2.5 billion to develop the TYK2 inhibitor acquired from Nimbus across as many as 11 new indications.
Nimbus Therapeutics has an average portfolio attrition rate of 75%, meaning it terminates three-quarters of its drug discovery programs.